Xcellbio, AmplifyBio Partner to Manufacture Solid Tumor-Targeting TCR-T Cell Therapy

Xcell Biosciences Inc. (Xcellbio), a technology company focused on cell and gene therapy manufacturing applications, and AmplifyBio, a contract development and manufacturing organization, have launched a partnership designed to streamline and improve the manufacturing process for engineered T-cell receptor (TCR) therapies targeting solid tumors.
 
“There is a pressing need for more effective and potent therapies, and we believe that working with the Xcellbio team and their unique AVATAR Foundry platform will allow us to make significant progress in that journey, and the results from this work will help create a better sandbox for our clients,” said J. Kelly Ganjei, President and CEO of AmplifyBio.

Boosting the Fitness & Potency of T-Cells

Across the cell and gene therapy field, scientists are looking for ways to boost the fitness and potency of T cells to turn them into more effective therapies for solid cancers, bringing therapeutic options to patients that are not available today.
 
“Current cell therapies have been highly effective for liquid tumors, but little progress has been made for the vast majority of patients with solid tumors. With low oxygen levels, low pH, and other hostile factors, the microenvironment within solid tumors makes it very difficult for T cells to kill cancer cells,” said James Lim, co-founder and Chief Scientific Officer of Xcellbio. “Our joint development work with AmplifyBio will demonstrate how the AVATAR Foundry will improve the manufacturability and potency of engineered TCRs by significantly reducing manufacturing times and utilizing non-viral workflows to produce scalable and cost-effective therapies.”
 
Xcellbio’s AVATAR Foundry platform is a cGMP cell therapy manufacturing platform that delivers novel capabilities for improving the potency of cell and gene therapies. In this partnership, scientists from AmplifyBio will work with the Xcellbio team to develop novel cell therapy manufacturing methods based on the AVATAR Foundry platform.
 
The efforts will focus on identifying key elements for successful manufacture of TCR therapies, such as product characterization matrix, correlation to metabolic profile, and potency. An IND filing is expected next year to target human papillomavirus-positive (HPV+) tumors using an engineered TCR therapy.
 
Brian Feth, co-founder and CEO at Xcellbio, commented: “We are pleased to team up with AmplifyBio, which has a strong track record in supporting the discovery, development, and manufacture of candidate therapies. We’re excited to work together to demonstrate that T cells grown in the AVATAR system can achieve higher potency and greater tumor-killing activity compared to T cells grown in traditional incubators. This has tremendous potential to one day make a difference for patient care.”
 
Scientists from AmplifyBio and Xcellbio will present their joint poster, “Adapting T Cells for the Tumor Microenvironment (TME) During Manufacturing for Improved Anti-Tumor Potency,” at ISCT 2024.